久久久久国产成人精品亚洲午夜,成人免费毛片一区二区三区,国产成人久久精品激情91,国产成人无码精品久久久免费,精品欧美国产一区二区三区不卡,国产成人一区二区三区影院,国产精品久久久久久,久久久WWW成人免费精品,欧美91精品久久久久网免费

熱門搜索:A549    293T 金黃色葡萄球菌 大腸桿菌 AKK菌
購物車 1 種商品 - 共0元
當(dāng)前位置: 首頁 > ATCC代理 > Panc 02.03
最近瀏覽歷史
聯(lián)系我們
  • 0574-87157013
  • mingzhoubio@163.com
  • 浙江省寧波市鎮(zhèn)海區(qū)莊市街道興莊路9號
  • 創(chuàng)e慧谷42號樓B幢401室
Panc 02.03
Panc 02.03
規(guī)格:
貨期:
編號:B165480
品牌:Mingzhoubio

標(biāo)準(zhǔn)菌株
定量菌液
DNA
RNA

規(guī)格:
凍干粉
斜面
甘油
平板


產(chǎn)品名稱 Panc 02.03
商品貨號 B165480
Organism Homo sapiens, human
Tissue pancreas
Cell Type Epithelial
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease adenocarcinoma
Age 70 years
Gender female
Ethnicity White
Storage Conditions liquid nitrogen vapor phase
Derivation
Panc 02.03 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma.
Clinical Data
70 years
female
White
Antigen Expression
MHC class I +; MHC class II -
Oncogene K-ras + RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
Genes Expressed
cytokeratins 7 and 18
Cellular Products
cytokeratins 7 and 18
Tumorigenic Yes
Effects
Yes, forms tumors in nude or SCID mice
Comments
The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine.
The cells have a reported plating efficiency of 100%.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
  • 10 Units/ml human recombinant insulin
  • fetal bovine serum to a final concentration of 15%

Subculturing Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.03% (w/v) EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C

Subculture Ratio: 1:3 to 1:4
Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994

Cryopreservation
Freeze Medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage Temperature: Liquid nitrogen vapor phase
Culture Conditions
Atmosphere: Air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 11,12
D13S317: 12
D16S539: 11
D5S818: 12,13
D7S820: 9,10
THO1: 6
TPOX: 9,12
vWA: 17
Population Doubling Time 28.2 hrs
Name of Depositor EM Jaffee
Deposited As human
Year of Origin 1995
References

Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

梅經(jīng)理 17280875617 1438578920
胡經(jīng)理 13345964880 2438244627
周經(jīng)理 17757487661 1296385441
于經(jīng)理 18067160830 2088210172
沈經(jīng)理 19548299266 2662369050
李經(jīng)理 13626845108 972239479
旺苍县| 醴陵市| 广昌县| 宁城县| 富川| 洛宁县| 织金县| 武川县| 泰州市| 香河县| 南乐县| 洛浦县| 深水埗区| 铁岭县| 肇东市| 平利县| 天长市| 苏尼特右旗| 肥西县| 双鸭山市| 柞水县| 松阳县| 班玛县| 临海市| 拉孜县| 浦江县| 津市市| 中山市| 大兴区| 曲水县| 嘉祥县| 西盟| 盐池县| 柏乡县| 乐至县| 陆丰市| 凤山县| 肇庆市| 弥勒县| 金阳县| 襄垣县|